Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow IONIS PHARMACEUTICALS INC

Get SEC filing alerts via email and in your feed for IONIS PHARMACEUTICALS INC

IONS

IONIS PHARMACEUTICALS INC

About IONIS PHARMACEUTICALS INC

Ionis Pharmaceuticals is a biotech company specializing in RNA-targeted therapeutics. It develops and commercializes medicines for serious diseases across neurology, cardiology, and rare genetic disorders. Its core products include antisense and siRNA medicines, with a focus on genetic and neurodegenerative conditions. The company partners with global pharma firms, leveraging innovative technology to deliver life-changing treatments and generate revenue through product sales, royalties, and milestone payments.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from IONIS PHARMACEUTICALS INC

1
1
IONIS PHARMACEUTICALS INC Ionis Pharmaceuticals Reports 87% Revenue Growth to $246.1 Million in Latest Quarter

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
IONIS PHARMACEUTICALS INC Ionis Pharmaceuticals Reports 2025 Financial Results with $943.7 Million Revenue

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
IONIS PHARMACEUTICALS INC Ionis Pharmaceuticals Reports 17% Revenue Growth in Q3 2025, Despite Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
IONIS PHARMACEUTICALS INC Ionis Pharmaceuticals Reports 100% Revenue Growth to $452M in Latest Quarter

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
IONIS PHARMACEUTICALS INC Ionis Pharmaceuticals Reports 10% Revenue Growth to $131.6 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
IONIS PHARMACEUTICALS INC Ionis Pharmaceuticals Reports $705.1M Revenue Decline and $453.9M Net Loss for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
IONIS PHARMACEUTICALS INC Ionis Pharmaceuticals Reports Mixed Q3 Results, Net Loss Improves

Via official filing (AI summary) | over 1 year ago | 0 comments